**Review Article**

**Gestational diabetes: risk factors and recent advances in its genetics and treatment**

Clive J. Petry*

Department of Paediatrics, University of Cambridge, Cambridge, UK

(Received 17 September 2009 – Revised 8 March 2010 – Accepted 22 March 2010 – First published online 21 May 2010)

The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study of over 23,000 diabetes-free pregnancies has shown that at a population level an unequivocal linear relationship exists between maternal glucose concentrations around the beginning of the third trimester of pregnancy and the risk of their baby being born above the ninetieth centile for weight. With the rising incidence of gestational diabetes (GDM) across the developed world, largely paralleling the increased prevalence of obesity, there has been a sharp increase in the risk of pregnancy complications developing related to the birth of macrosomic babies. The associated additional long-term complications of GDM pregnancies means that in the future there is likely to be a large increase in the incidence of type 2 diabetes and associated conditions in both the mothers and their affected offspring. The present review seeks to highlight recent advances and remaining gaps in knowledge about GDM in terms of its genetics (where some of the recently discovered polymorphic risk factors for type 2 diabetes have also proved to be risk factors for GDM) and its treatment by diet, exercise and drugs.

**Pregnancy: Fetal growth: Glycaemic index**

**Introduction – what is gestational diabetes?**

Moderate to severe maternal hyperglycaemia in pregnancy has unique diabetes-related risks in that there are potential long-term consequences for two individuals rather than just one: the mother and her unborn baby. Gestational diabetes (GDM) has been defined as any degree of glucose intolerance with onset or first recognition during pregnancy, to differentiate it from pre-diagnosed type 1 or type 2 diabetes or maturity-onset diabetes of the young (MODY) in women that get pregnant. This broad definition of GDM therefore includes women whose glucose intolerance develops during pregnancy and those that had pre-existing diabetes which had not been diagnosed before pregnancy. The distinction here is important as, unlike most unborn babies of women who develop glucose intolerance in pregnancy, those of women with pre-existing diabetes can be exposed to hyperglycaemia in the first two trimesters of pregnancy resulting in an increased risk of a range of both isolated and multiple cardiovascular and other abnormalities (including central nervous system and musculoskeletal defects). To try and clarify the situation, the Consensus Panel of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) recently recommended that high-risk women found to have diabetes at their initial prenatal visit should be diagnosed as having overt diabetes rather than GDM.

To diagnose GDM at a later visit it was recommended that one or more of the following plasma glucose thresholds should be equalled or exceeded during a 75 g oral glucose tolerance test: 5·1 mmol/l (fasting), 10·0 mmol/l (1 h post-load) and 8·5 (2 h post-load) mmol/l. One of the long-term risks for the mother with GDM is the development of type 2 diabetes later in life, but in a minority of women with GDM the glucose intolerance does not disappear post-partum. Whether this type of diabetes should be considered gestational or type 2 from its onset is unclear as: (i) if the new IADPSG recommendations are not implemented undiagnosed type 2 diabetes may have been present in these women before pregnancy; (ii) type 2 diabetes and diabetes that develops during pregnancy have a number of shared risk factors and are hypothesised by some to be the same condition; and (iii) the continuing glucose intolerance may be autoimmune related and more like type 1 diabetes than type 2. Such uncertainties over its diagnosis and lack of agreement over which screening protocols or diagnostic thresholds should be used make GDM prevalence estimates difficult, but it is generally considered to be somewhere between 1 and 14 % of all pregnancies depending on the population in question. What is clearer, however, is that in line with increased prevalences of particularly type 2 diabetes, the incidence of GDM is rising wherever obesity is becoming more prevalent.

**Abbreviations:** GDM, gestational diabetes; GI, glycaemic index; HLA, human leucocyte antigen.

*Corresponding author:* Dr Clive J. Petry, fax +44 1223 336996, email cjp1002@cam.ac.uk

doi:10.1017/S0007114510001741
GDM has long been known to raise the risk of macrosomia in the offspring, with the high glucose levels thought to cross the placenta and stimulate fetal insulin secretion which then acts as a growth factor\(^{(11)}\). Macrosomia brings its own difficulties such as increased risks of shoulder dystocia, brachial plexus injuries and clavicular fractures in natural deliveries leading to a higher requirement for birth by Caesarean section\(^{(12)}\). Other short-term risks associated with GDM in the mother are pregnancy-induced hypertension and pre-eclampsia, urinary tract infections, pyelonephritis and polyhydramnios (which itself leads to increased risk of abruption placentae). There is also increased risk of stillbirth and congenital abnormalities\(^{(13)}\). Short-term risks for the baby include neonatal hypoglycaemia (caused by the excess insulin produced initially in response to the maternal hyperglycaemia, once the baby has been born and that drive has been removed), hyperbilirubinaemia, hypocalcaemia, respiratory distress syndrome, and polycythaemia\(^{(12)}\). Having been diagnosed with GDM, as already stated, the mother is subsequently at increased risk of developing type 2 diabetes\(^{(5,6)}\), with the prospectively studied Coronary Artery Risk Development in Young Adults (CARDIA) cohort showing that this risk is independent from preconception glucose tolerance and obesity or a family history of diabetes\(^{(14)}\). As well as long-term risks for herself, in her offspring there is increased risk of childhood obesity\(^{(15,16)}\), and type 2 diabetes and hyperlipidaemia in adolescence and beyond\(^{(17–21)}\). Where the baby is female, exposure to maternal hyperglycaemia \textit{in utero} increases their own risk of subsequently developing GDM in their own pregnancies\(^{(22)}\). This metabolic programming by \textit{in utero} exposure to hyperglycaemia therefore is a transgenerational effect that may contribute to the expected huge increase in prevalence of type 2 diabetes worldwide\(^{(23)}\), especially given the increasing prevalence of obesity.

Risk factors for gestational diabetes

Like all other major forms of diabetes, GDM results from inadequate insulin secretion for the degree of insulin resistance. As has already been stated, the risk factors for GDM (Table 1) share similarities with those for type 2 diabetes. In fact, the relatively high risk that women who develop diabetes in pregnancy have for subsequently developing type 2 diabetes suggests that certain forms of these conditions have common precedents, the physiological insulin resistance of pregnancy manifesting the disease state somewhat earlier than would otherwise occur. This insulin resistance is likely to be caused by placental hormones and/or proteins, such as placental growth hormone, cortisol, human placental lactogen\(^{(12)}\) or TNF-\(\alpha\)\(^{(24)}\), given that for the majority of women with GDM the glucose intolerance resolves post-partum\(^{(6)}\). Risk factors for GDM must therefore either contribute directly to this insulin resistance and/or relative insulin deficiency, or they must be associated or correlated with other factors that do. The traditional, and most cited, risk factors for GDM are high maternal age, weight and parity (which are often correlated), a family history of type 2 diabetes and the previous birth of a macrosomic baby\(^{(25)}\). Of the more recently described risk factors, high or low maternal birth weights\(^{(26)}\) are important, given the previously described transgenerational effects. Other potential risk factors that have been variably associated with higher maternal glucose concentrations in the third trimester of pregnancy and which therefore may alter GDM risk include multiple pregnancy (for a review, see Norwitz \textit{et al.}\(^{(27)}\)) and short stature\(^{(28)}\).

Having briefly highlighted what GDM is, and what its risk factors are, I now want to focus the remainder of the present review on recent advances in two areas that have developed rapidly, the genetics of GDM and its treatment. Of the current options available to manage GDM, all women will require dietary intervention (and probably exercise) whilst some will require additional pharmacological therapy. Pinpointing genetic risk factors for GDM will help identify mechanisms underlying its pathophysiology and potentially may reveal new preventative strategies and even therapeutic targets. Ultimately, increased knowledge about the genetics and treatment of GDM will help prevent complications in both the mother and child. Readers wanting a review of other established aspects of the condition are referred to other excellent up-to-date reviews of the subject\(^{(6,12,25–29–31)}\).

Genetics of gestational diabetes

The cause of familial aggregation of GDM with a first-degree relative who has or has previously had GDM or another type of diabetes is likely to have both genetic and (non-genetic) environmental components, especially given that in females both low and high birth weights\(^{(26)}\) are associated with the future development of GDM in their own pregnancies. This suggests that a pregnant woman with poorly controlled, pre-existing type 1 diabetes is at increased risk of giving birth to a macrosomic baby who, if female, is subsequently at increased risk of developing GDM and/or type 2 diabetes\(^{(32)}\) in her own pregnancies and beyond. As well as such metabolic programming effects, genetic variation also plays its part in regulating size at birth\(^{(33)}\) and therefore risk of GDM in women with low or high birth weights.

The collection of large DNA cohorts, combined with improvements in DNA technologies, has driven rapid increases in knowledge about the genetics of all major forms of diabetes in recent years. For type 2 diabetes, the

<table>
<thead>
<tr>
<th>Table 1. Risk factors for gestational diabetes (GDM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factors</td>
</tr>
<tr>
<td>Previous history of GDM or impaired glucose tolerance</td>
</tr>
<tr>
<td>Obesity</td>
</tr>
<tr>
<td>Ethnicity (higher risk for those of African, Hispanic, South or East Asian, Native American or Pacific Islander descent)</td>
</tr>
<tr>
<td>Family history of GDM or type 2 diabetes (especially in first-degree relatives)</td>
</tr>
<tr>
<td>Advanced maternal age</td>
</tr>
<tr>
<td>Excess weight gain in pregnancy</td>
</tr>
<tr>
<td>Previous history of macrosomic baby</td>
</tr>
<tr>
<td>Previous history of stillbirth</td>
</tr>
<tr>
<td>Previous history of baby with congenital abnormality</td>
</tr>
<tr>
<td>Pregnancy-induced or pre-existing hypertension</td>
</tr>
<tr>
<td>Other insulin-resistant conditions (for example, metabolic syndrome, polycystic ovary syndrome)</td>
</tr>
<tr>
<td>Smoking during pregnancy</td>
</tr>
<tr>
<td>Maternal high or low birth weight</td>
</tr>
<tr>
<td>Current glycosuria</td>
</tr>
<tr>
<td>High parity</td>
</tr>
</tbody>
</table>
most common form, studies of large DNA cohorts that have been assessed by whole-genome association have allowed the elucidation of genetic markers of risk in or near genes that would have been extremely unlikely to have been considered using a candidate approach with an a priori hypothesis. So whereas 5 years ago there were only two markers that were robustly associated with type 2 diabetes, gained through linkage and/or candidate genetic association studies (the PPARγ and K channel, inwardly rectifying, subfamily J, member 11 variants(33), the list now stands at more than twenty-two loci(35–40) (Table 2). Subsequent to these studies at least ten of these loci (KCNJ11, TCF7L2, CDKAL1, KCNQ1, CDKN2A/CDKN2B, HHEX/IDE, IGF2BP2, SLC30A8, TCF2, FTO) have now been associated with GDM risk(33,41–46), which again is not surprising given the common findings for GDM are often based on relatively small sample sizes (relative to sizes used to discover new markers of type 1 diabetes risk). However, studies of familial clustering of diabetes show an increased prevalence of type 1 diabetes in offspring of mothers with GDM(39). This suggests that GDM may also be caused by genetic variation that predisposes a woman to autoimmune type 1 diabetes or late autoimmune diabetes of adulthood(49). Indeed, about 10% of women with GDM may have an autoimmune form of this condition(50). In general, studies of human leucocyte antigen (HLA) markers in relation to autoimmune GDM have proved inconsistent due to small sample sizes and ethnically mixed study groups(51), with some studies showing no linkage or association(52–54). However, others have shown positive relationships with markers such as HLA-DR3 or HLA-DR4 in insulin cell antibody-positive women with GDM(55), or indeed any woman with GDM(56,57), HLA-Cw7(58) and HLA-DR3-DQ2, DR4-DQ8 and MHC class I chain-related gene A (MICA) 5/0/5–1 in autoantibody-positive women with GDM(59), and HLA-DR7 dQ2, DR9-DQ9, DR14-DQ5, MICA5*0602(60) and DQB1*0602(61) in women with GDM who were not autoantibody positive.

Not surprisingly, given the link between reduced size at birth and increased subsequent risk of developing type 2 diabetes(62), some of the type 2 diabetes genetic risk loci have also recently been shown to be associated with low birth weight(63). In one study, participants with risk alleles for the

Table 2. Genes that either contain or are near polymorphic markers that are associated with type 2 diabetes(35–40)

<table>
<thead>
<tr>
<th>Gene(s)</th>
<th>Human Genome Organisation (HUGO) abbreviation</th>
<th>dbSNP marker reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription factor 7- like 2</td>
<td>TCF7L2</td>
<td>rs7903146</td>
</tr>
<tr>
<td>Haematopoietically expressed homebox/insulin-degrading enzyme/kinesin family member 11</td>
<td>HHEX/IDE/KIF11</td>
<td>rs7923837</td>
</tr>
<tr>
<td>CDK5 regulatory subunit-associated protein 1- like 1</td>
<td>CDKAL1</td>
<td>rs10946398</td>
</tr>
<tr>
<td>Potassium channel, inwardly rectifying, subfamily J, member 11</td>
<td>KCNQ11</td>
<td>Lys 23 rs5219</td>
</tr>
<tr>
<td>Peroxisome proliferator-activated receptor-gamma</td>
<td>PPARG</td>
<td>Pro 12 rs1801282</td>
</tr>
<tr>
<td>Synapsin II/peroxisome proliferator-activated receptor-gamma</td>
<td>SYN2/PPARG</td>
<td>rs17036101</td>
</tr>
<tr>
<td>Potassium channel, voltage-gated, KQT-like subfamily, member 1</td>
<td>KCNQ2</td>
<td>rs2237895, rs2273892, rs2283228</td>
</tr>
<tr>
<td>Cyclin-dependent kinase inhibitor 2A and 2B</td>
<td>CDKN2A/B</td>
<td>rs10811661</td>
</tr>
<tr>
<td>Insulin-like growth factor 2 mRNA-binding protein 2</td>
<td>IGF2BP2</td>
<td>rs4402960</td>
</tr>
<tr>
<td>Solute carrier family 30 (zinc transporter), member 8</td>
<td>SLC30A8</td>
<td>rs13266634</td>
</tr>
<tr>
<td>Fat mass- and obesity-associated gene</td>
<td>FTO</td>
<td>rs9999609</td>
</tr>
<tr>
<td>Notch, drosophila, homologue of, 2</td>
<td>NOTCH2</td>
<td>rs10923931</td>
</tr>
<tr>
<td>Thyroid adenoma-associated gene</td>
<td>THADA</td>
<td>rs7578597</td>
</tr>
<tr>
<td>A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 9</td>
<td>ADAMTS9</td>
<td>rs4607103</td>
</tr>
<tr>
<td>Juxtaposed with another zinc finger gene 1</td>
<td>JAZF1</td>
<td>rs864475</td>
</tr>
<tr>
<td>Cell division cycle 123 homologue/calciuim/calmodulin-dependent protein kinase 1-delta</td>
<td>CDC123/CAMK1D</td>
<td>rs12779790</td>
</tr>
<tr>
<td>Tetraspanin 8/leucine-rich repeat-containing G protein-coupled receptor 5</td>
<td>TSPAN8/LGR5</td>
<td>rs7961501</td>
</tr>
<tr>
<td>Dermcin</td>
<td>DCD</td>
<td>rs1153188</td>
</tr>
<tr>
<td>A disintegrin and metalloproteinase domain 30</td>
<td>ADAM30</td>
<td>rs2641348</td>
</tr>
<tr>
<td>Vascular endothelial growth factor A</td>
<td>VEGFA</td>
<td>rs9472138</td>
</tr>
<tr>
<td>B-cell CLL/lymphoma 11A</td>
<td>BCL11A</td>
<td>rs10490072</td>
</tr>
</tbody>
</table>

dbSNP, Single Nucleotide Polymorphism Database.
CDKAL1 and HHEX-IDE loci were born on average 80 g lighter than those participants without the risk alleles(71). Given that these two loci are also associated with the development of GDM(7), there is a clear link between the genetic risk of GDM and alterations in fetal growth. Following on from an earlier report by Haig(72), we recently proposed that as well as the mother’s genes contributing to her risk of developing GDM in pregnancy, polymorphic variation in fetal growth genes could also contribute to risk of GDM in the mother(73). The basis for this relies on the kinship theory of pregnancy(74) (sometimes called the conflict theory) which suggests that genes inherited from the father will tend to try and boost fetal growth, whilst those inherited from the mother will try and limit or restrict it. Mitochondrial genes, which are exclusively inherited from the mother, at least when not affected by paternal leakage, heteroplasy or recombination(75), and imprinted genes(76), where the copy inherited from one of the parents is inactivated depending on both the gene in question and the developmental stage of the offspring, are ideally suited to mediate these alterations in growth through altering the availability and transfer of nutrients to the fetus. There are a number of novel studies in human subjects indirectly linking genetic variation in the fetus with changes in maternal glucose concentrations in pregnancy. First, a large observational study stratifying pregnancies according to the sex of the offspring found an increased incidence of GDM in women carrying boys rather than girls(77), possibly resulting from a higher dietary energy intake in pregnant women carrying boys(78). Second, another large observational study found higher maternal glucose concentrations in women carrying twins than in those carrying only one baby(79). In a retrospective study of women carrying offspring with Beckwith–Wiedemann syndrome there was a trend for an increased risk of the women developing GDM compared with when the same women carried non-affected siblings(80). In our own studies of a common variant in the imprinted, maternally expressed H19 gene, when transmitted to the baby the variant was associated with maternal glucose levels in pregnancy(81).

To develop the concept that variation in fetal growth genes is able to alter maternal risk of GDM we recently assessed the maternal glucose tolerance of phenotypically wild-type mice carrying H19 knockout offspring from those carrying only wild-type offspring. However, by day 16 of the 21 d pregnancy, in the third trimester about the time when GDM becomes more prevalent in humans(85), the areas under the curves of intra-peritoneal glucose tolerance tests performed in phenotypically wild-type mice carrying H19 knockout offspring was 28% higher than those from wild-type mice carrying only wild-type offspring. Whilst the reason for this could be the removal of a functional H19 gene which normally acts to repress Igf2 expression(86), it could also be that the removal of the Igf2 control element effectively doubles Igf2 expression in the growing fetuses and placentas(83) (how this might influence maternal glucose concentrations is shown in Fig. 1). Whilst further mechanistic studies are ongoing, these results are proof of principle that altering the fetal gene is able to alter maternal glucose tolerance in pregnancy.

The relevance of this to humans is difficult to test directly due to the confounding effects of the mothers’ own genes on their glucose tolerance in pregnancy(87,88) and the fact that the fetus inherits half of its genes from its mother so that it is therefore difficult to separate out which genes are having which effect(73). Nevertheless, this can be partially overcome when testing associations of common polymorphic variation in paternally expressed imprinted genes, studies of which have already begun.

In summary, progress in the study of the genetics of GDM is hampered by such factors as the heterogeneous causes and criteria for diagnosing the condition and its relative scarcity(9). What is clear is that there is a polygenic rather than single gene risk for its development(7). Not surprisingly, given that GDM can be split into non-autoimmune and autoimmune forms, genes associated or linked with GDM tend to be associated with type 2 diabetes for the non-autoimmune form or type 1 diabetes for the rarer autoimmune form. If larger GDM cohorts could be recruited, possibly by pooling existing data and sample sets, genome wide association followed by candidate gene studies would have greater statistical power to detect additional associations of genes with GDM. Such genes are likely to include some of those already associated with either type 1 or 2 diabetes (and possibly offspring birth weight). For a more complete set of genes associated with the risk of developing GDM it is possible that assessments of polymorphic variation in fetal growth-related genes may also be needed(73).

Prevention and treatment of gestational diabetes

The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, which investigated the glucose tolerances of over 23,000 women with diabetes-free pregnancies, recently showed a strong linear relationship between circulating maternal glucose concentrations in the third trimester of pregnancy and risk of offspring birth weight being over the ninetieth centile(89), partially explained by changes in fetal adiposity(90). Whilst before the publication of these results it was apparent that macrosomias were often born to mothers with the most severely impaired glucose tolerance in pregnancy, suggesting a link between increased fetal growth and high maternal glucose concentrations, it is now clear that there is a strong continuous association between maternal glucose tolerance and a number of different adverse pregnancy outcome events even in the sub-diabetes range. This suggests that even in the presence of unalterable GDM risk factors such as multiple genetic risk alleles, optimising treatments and therefore improving maternal glucose tolerance is beneficial. Indeed the importance of treatment was shown by a randomised controlled trial of 1000 women with GDM where lower rates of adverse pregnancy outcome events such as macrosomia, pre-eclampsia, admissions to neonatal intensive care units and perinatal complications were found in women who performed blood glucose monitoring, were given dietary advice and treatment if necessary, in comparison...
with women who received just routine care\(^\text{(91)}\). To reduce the risk of these complications there are three strategies used for the treatment of GDM: dietary modification, regulated exercise and pharmacological. Women with the severest form of the condition, which may become evident in the first trimester of pregnancy rather than the more common third trimester\(^\text{(85)}\) and/or might be autoimmune mediated\(^\text{(9)}\), are likely to require all three forms of treatment. Most women though (up to 90% in the UK\(^\text{(92)}\)) may be adequately treated using just the first two strategies. However it is managed, the Fifth International Workshop on Gestational Diabetes Mellitus recommended that current maternal capillary blood glucose targets should be: fasting below 5.3 mmol/l, 1 h after starting a meal below 7.8 mmol/l and 2 h after starting a meal below 6.7 mmol/l\(^\text{(93)}\).

**Dietary modification**

All women with GDM have to consume a diet that is sufficiently nourishing for both her and her unborn offspring, without encouraging the hyperglycaemia and excessive weight gain that can over-stimulate fetal growth and adipsity. Whilst ketoacidosis resulting from the hyperglycaemia of GDM is rare\(^\text{(94)}\), it can occur as a result of starvation in a woman who is trying to drastically lose weight to improve her glucose tolerance\(^\text{(95)}\). Such action is dangerous for both the mother and her unborn baby\(^\text{(96)}\). Similarly, maternal hypoglycaemia should be avoided as much as possible in GDM pregnancies treated with insulin\(^\text{(97)}\) to avoid a restraining effect on fetal growth. To satisfy these various demands, the following dietary principles have been suggested as suitable for someone

---

**Fig. 1.** Schematic representation of how the fetal genotype, in this case fetal mice that have the H19 gene and 10 kb 5’-flanking region disrupted, may cause an increase in maternal blood glucose concentrations so as to increase their potential glucose supply and help enhance their growth\(^\text{(73,82)}\). It is hypothesised that the increased Igf2 expression in these mice causes increased expression of various placental hormones (and other proteins) that are secreted into the maternal circulation and have metabolic effects that lead to the raising of maternal blood glucose concentrations.
with GDM\(^{97\textnormal{-}99}\), (i) eating regular small meals of slowly absorbed carbohydrate to maintain blood glucose concentrations; (ii) taking similar portions of carbohydrate at meals daily (especially if the GDM is not treated by insulin); (iii) allowing the consumption of a moderate amount of sugar-containing foods as long as it neither promotes hyperglycaemia nor excessive weight gain; (iv) eating at least five portions of fruit and vegetables per d; (v) eating low-fat dairy foods and attempting to drink a pint of milk or its equivalent every day and meat/fish/poultry or alternatives; (vi) attempting to eat two portions of oily fish per week. In addition the recently revised guidelines of the UK National Institute for Health and Clinical Excellence for pregnant women with GDM suggest that those whose pre-pregnancy BMI is greater than 27 kg/m\(^2\) should restrict their energy intakes to 105 kJ/kg per d or less and to combine this with moderate exercise of at least 30 min duration per d\(^{103}\). Overall, these principles are largely based on consensus opinion rather than evidence from pregnant women, however, due to the lack of available data on total energy and nutrient-partitioning requirements in women with GDM\(^{93,106,101}\).

Of the principles listed above, the diets which may have the best potential to fulfil all the criteria are those with a low glycaemic index (GI). These diets based on the consumption of slowly absorbed carbohydrates can reduce postprandial glycaemia in people with no impairment of glucose tolerance\(^{102}\). For GDM this slow absorption of the carbohydrate may theoretically lessen episodes of both hyper- and hypoglycaemia. Hypothetically these diets could also be used in high-risk pregnant women to prevent the development of GDM altogether, especially since women with newly diagnosed GDM were found to consume less low-GI carbohydrate than pregnant women who remained glucose tolerant in one study\(^{103}\). Unlike observations from pregnant women in most developed countries, cross-sectional studies in populations from Kenya, Nigeria and Tanzania of pregnant and non-pregnant women without diabetes who all ate low-GI diets found that the pregnant women had slightly improved glucose tolerance as pregnancy progressed, and near term better glucose tolerance than non-pregnant women\(^{104\textnormal{-}106}\). These studies therefore suggest the superiority of these diets for pregnant women over those generally consumed in more developed countries, at least in terms of maternal glucose tolerance.

The efficacy of diets used to prevent GDM was recently addressed by meta-analysis\(^{107}\) of three previous trials, one comparing effects of differential fibre diets\(^{108}\), high-fibre diets frequently having a low GI\(^{109}\), and two (published as multiple papers) comparing effects of diets with differing GI\(^{109\textnormal{-}114}\). Fraser et al.\(^{108}\) compared effects of a high-fibre diet against those of a ‘standard’ pregnancy diet on circulating glucose and insulin concentrations in a total of twenty-five non-obese primigravid pregnant women, starting the randomly allocated diet after 27 weeks of gestation and remaining on them for the following 8 weeks. The consumption of the high-fibre diet was not associated with a change in glucose tolerance, as assessed by % g oral glucose tolerance tests, or with a change in offspring birth weight. The two other trials included in the meta-analysis\(^{107}\) compared the effects of the consumption of low- against high-GI diets. Clapp\(^{109}\) recruited twenty women pre-pregnancy and placed all women on a low-GI diet with a standardised exercise regimen until 8 weeks of gestation when half of the women were swapped to consume a high-GI diet, whereas in the study of Moses et al.\(^{113}\) study diets were commenced in sixty-two pregnant women after recruitment at 12–16 weeks of gestation. Dietary interventions continued in both studies until 36 weeks of gestation. The meta-analysis of these studies found that the consumption of the low-GI diet led to a reduction in risk of the women having large-for-gestational-age infants\(^{107}\). Both studies found that offspring of mothers who consumed a low-GI diet had lower birth weights\(^{109,113}\), which was confirmed in the meta-analysis when a fixed-effects model was used, although significance was lost when a random-effects model was used\(^{107}\). Offspring ponderal indexes at birth and maternal fasting glucose concentrations were significantly lower in women consuming a low-GI diet, however, in the meta-analysis when both fixed- and random-effects models were used. The two studies exhibited conflicting data regarding maternal weight gain\(^{109,113}\), along with particularly evident heterogeneity for all the study findings with the exception of maternal fasting glucose concentrations\(^{107}\). The summary of the meta-analysis was that for clinical practice implications the trials were inconclusive due to the small number of studies published so far, the small number of participants in each study and the high degree of heterogeneity amongst the variables measured. However, it was noted that low-GI diets appear promising and that several larger trials of low-GI diets are under way\(^{107}\). More recently a trial of sixty-three women with GDM found that, without altering obstetric outcomes, a lower proportion (nine out of thirty-one) of women consuming a low-GI diet for up to 9 weeks (28 to 37 weeks of gestation) met the criteria for insulin requirement than those consuming a higher-GI diet (nineteen out of thirty-two)\(^{115}\). Of the nineteen women consuming a high-GI diet that met the criteria for requirement for insulin treatment, nine women subsequently managed to avoid this by switching to a low-GI diet. Indeed, in the prospective Nurses’ Health Study II cohort, the consumption of high-glycaemic load (i.e. the product of the GI and the carbohydrate content) diets with low fibre contents before pregnancy doubled the risk of developing GDM when pregnant during 8 years of follow-up\(^{116}\). Despite the limitations in the available data concerning the consumption of low-GI diets in pregnancy, the revised UK National Institute for Health and Clinical Excellence guidelines for women with GDM suggest that they should consume diets containing, where possible, carbohydrates from low-GI sources\(^{92}\). It is important that this is achieved without introducing other dangers, however, as potentially could be found with a diet that focused solely on having a low GI without consideration of other dietary requirements. As an extreme example, a pregnancy diet that included excessive cured meat consumption and had a deficit in phytochemical-rich plant-based foods could have a low GI but be associated with an increased risk of certain tumours developing in the offspring\(^{117,118}\).

Of dietary studies not primarily related to the GI, a recently published 10-year prospective follow-up of the Nurses’ Health Study II cohort of over 11 000 women found that higher (more than four servings per week) consumption of sugar-sweetened cola before pregnancy was associated with a 22% increased risk of developing GDM\(^{119}\). However,
this increased risk was not found with the consumption of other sugar-sweetened or diet beverages, making the factor in cola that causes this association difficult to ascertain (presumably being some sort of interaction between effects of the sugar sweetener and the cola flavouring or colouring). In the same cohort, consumption of a diet before pregnancy that contains large amounts of red or processed meat was also associated with an increased risk of women developing GDM\(^ (120)\). In contrast to studies of dietary habits before pregnancy, a prospective cohort study of over 1700 women found that no particular dietary factor consumed early in pregnancy strongly predicted the development of GDM, other than a minor increased risk associated with the consumption of n-3 fatty acids\(^ (121)\).

In summary, the diet of a woman with GDM needs to provide sufficient nourishment for both her and her fetus without encouraging either excess weight gain or hyperglycaemia, both of which can cause complications for both mother and baby. Whilst dietary recommendations have been made, these are largely based on consensus opinion rather than evidence-based facts due to a lack of available data. The diets that probably have the best potential to best fulfil these recommendations are those with a low GI. Meta-analysis of studies assessing such diets showed a lower risk for the offspring being born large for gestational age and a lower offspring ponderal index at birth, although the overall beneficial effect of consuming a low-GI diet was inconclusive in pregnancy due to the small number of participants studied so far and the heterogeneity of results\(^ (107)\).

### Exercise

In addition to the dietary effects outlined, the development of insulin resistance in mid to late pregnancy can be lessened by exercise to reduce the risk of developing GDM (for a review, see Clapp\(^ (122)\)). However, a meta-analysis (published in 2006) of the prospectively studied effects of 6 weeks of 20–45 min of high-level exercise three times per week in a total of 114 pregnant women in their third trimester with GDM concluded that there was insufficient evidence to recommend that women with GDM should (or should not) enrol in exercise programmes\(^ (123)\). Despite this, it was stated that whilst it may have implications for the pregnancy, enrolment in an exercise programme may elicit lifestyle changes that could alter the woman’s risk of developing type 2 diabetes in the future\(^ (124)\). Rather like the meta-analysis for the treatment of GDM with low-GI diets\(^ (107)\), however, it was suggested that further randomised trials with larger sample sizes are needed before a definite recommendation for starting an exercise programme could be made. One similar randomised trial concerned with the potential prevention of GDM by exercise is already under way\(^ (124)\), the study investigators previously having found a small beneficial effect of exercise on the risk of developing GDM in a prospective cohort study of 1006 mainly Hispanic women\(^ (125)\).

Despite the lack of available evidence from convincing randomised trials, less robust but nevertheless supportive evidence for a beneficial effect of exercise on GDM pregnancies comes from studies such as the National Maternal Infant Health Survey where over 75,000 GDM pregnancies were categorised according to whether the mothers ‘exercised’ or not, where the exercise group gave birth to a lower proportion of large-for-gestational-age babies\(^ (126)\). Data from this survey also showed that exercising in pregnancy in previously inactive women reduced their risk of developing GDM\(^ (127)\). The reduction in large-for-gestational-age births was also observed in a non-randomised prospective study of ninety-six women with GDM (although in this case the exercise was combined with dietary restriction)\(^ (128)\). Other non-interventional studies showing a beneficial effect of exercise on the rate of development of GDM include an observational study of the effects of pre-gravid vigorous exercise in 851 pregnant women\(^ (129)\) and a prospective cohort study of 611 women of South Asian origin\(^ (130)\). Preliminary data would suggest that the amount of exercise needed to have an effect is actually quite small, however, as a study of ten women with GDM treated with diet and insulin found that a structured walking programme led to a reduction in post-exercise, fasting and postprandial capillary glucose concentrations, as well as a reduction in insulin requirements\(^ (131)\).

In summary, currently available evidence appears to suggest that there might be a stronger role for exercise in the prevention of GDM than in its treatment. There is a need for larger prospective studies assessing both its potential beneficial and detrimental effects for women with GDM. However, unless it proves to be unsafe, even if there were few apparent benefits, undertaking regulated exercise in pregnancy may help elicit lifestyle changes in women with GDM which could reduce their risk of developing type 2 diabetes in later life\(^ (123)\).

### Pharmacological treatment

For some women, especially those with a relatively severe form of the condition that develops earlier than in the third trimester\(^ (85)\), GDM cannot be adequately controlled by diet and exercise alone. In these cases pharmacological treatment is required to reduce circulating maternal glucose concentrations and therefore its associated risks\(^ (132)\). Treatment options are similar to those for other forms of diabetes but with the need for extremely tight glucose control to reduce the risk of enhanced fetal growth and to have no adverse (for example, teratogenic) effects on the fetus if the drug used for treatment crosses the placenta. Subcutaneous injections of insulin are often therefore the treatment of choice due to its minimal transfer across the placenta and its dosage flexibility so that glucose control can be optimised.

Whilst regular human insulin is clinically safe, much attention has recently been focused on rapidly acting insulin analogues due to their ability to reduce postprandial hyperglycaemia whilst also reducing the risk of pre-prandial hypoglycaemia. In one randomised controlled study of 322 pregnant women with type 1 diabetes, treatment with insulin aspart (28B-aspartic acid-insulin), as well as reducing postprandial hyperglycaemia, was associated with a tendency toward fewer fetal losses and preterm deliveries than treatment with regular human insulin\(^ (133)\). In addition, the insulin analogue could not be detected in the fetal circulation and no increase in circulating concentrations of insulin antibodies or evidence of teratogenesis was found, suggesting that it is safe to use in pregnancy. Comparable results were found in a similar but smaller randomised, open-label trial of insulin aspart in women with GDM\(^ (134)\). Insulin lispro (B28-lysine,
B29-proline-insulin) has also been found not to appreciably cross the placenta\(^\text{135}\)\(^\text{15}\), and to have similar effects to insulin aspart in randomised controlled clinical trials of women with pre-existing type 1 or 2 diabetes\(^\text{136–138}\), so can also be considered safe to use in pregnancy\(^\text{139}\). There is a dearth of randomised controlled trials of the effects of treating GDM with longer-acting insulin analogues, hence neither insulin glargine (B21-glycine, B31, 32-arginine-insulin) nor insulin detemir (B29-lysine-myristic acid insulin) are licensed yet for use in pregnancy. Relatively small observational studies of pregnant women with diabetes suggest that glargine is well tolerated in pregnancy with acceptable perinatal outcomes\(^\text{140–143}\), although one study of fifteen women with type 1 diabetes treated with glargine found that the frequency of fetal femoral lengths less than the 50th centile in the second and third trimester was higher in treated women than in the women without diabetes\(^\text{144}\). Concern over the use of long-acting insulin analogues in pregnancy also stems from the suggestion that the long-term use of glargine, and possible other insulins\(^\text{145}\), to treat people with type 1 diabetes may be associated with an increase in the incidence of certain tumours\(^\text{145–148}\). This may result from glargine’s six-fold increased affinity for the insulin-like growth factor-I receptor in comparison with that of native insulin\(^\text{149}\). Overall then, although these studies testing the safety and efficacy of insulin treatment in pregnancy were mainly performed in pregnant women with pre-existing type 1 diabetes rather than GDM, their efficacy and safety are likely to be similar in women with GDM, where insulin treatment may be required for a shorter period of time in the pregnancy.

The aversion of some women to subcutaneous insulin injections and the requirement for education concerning its safe use and administration have led to the investigation of other oral hypoglycaemic agents to test their safety and efficacy for the treatment of GDM. Whilst there had been a number of previous reports of small studies (outlined in Cheung\(^\text{150}\)) of the use of metformin as a treatment (either as a sole agent or in conjunction with insulin injections) in recent years has been dominated by the Metformin in Gestational Studies study (MiG)\(^\text{151}\). Here 751 women with GDM in weeks 20 to 33 of pregnancy were randomly assigned to treatment arms with either metformin (with or without insulin) or insulin. Neither the composite rates of primary (a composite of neonatal hypoglycaemia, respiratory distress, need for phototherapy, birth trauma, 5 min Apgar score less than 7, or prematurity) nor secondary outcomes (neonatal anthropometric measurements, maternal glycaemic control, maternal hypertension, complications, post-partum glucose tolerance, and acceptability of treatment) differed between the two groups, with the exception that more women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again and there was a slight increase in the proportion of babies born preterm (<37 weeks). This increase was deemed to be of spontaneous rather than iatrogenic origin though and was not associated with an increased incidence of complications. There were therefore no serious adverse events that could be attributed to the use of metformin, although some of the offspring from this study are being monitored for any longer-term metabolic programming effects since metformin is able to cross the placenta\(^\text{152}\). A meta-analysis of studies where metformin has been used to treat GDM highlights the lower rates of neonatal hypoglycaemia in comparison with offspring of those mothers treated with insulin\(^\text{153}\). The other oral hypoglycaemic agent that has received most attention is gluburide, which, unlike metformin, does not appear to cross the placenta\(^\text{154}\). Here a randomised trial of 404 women with GDM found that treatment with gluburide was as effective as treatment with insulin without altering either primary or secondary endpoints\(^\text{155}\). A meta-analysis of this and other smaller studies (outlined in Cheung\(^\text{156}\)) showed no difference in infant birth weight, rates of congenital malformations, maternal glucose control or rates of Caesarean section\(^\text{153}\). These oral hypoglycaemic agents therefore seem to be as safe and efficacious as insulin for the treatment of GDM, at least in the short term.

In summary, insulin and currently available rapid-acting insulin analogues appear to be safe to use in pregnancy as they do not cross the placenta and are not associated with increased incidences of adverse pregnancy outcomes. For many women, insulin or its rapid-acting analogues are the first-line pharmacological treatment of GDM. In the short term at least, oral hypoglycaemic agents such as metformin and gluburide appear safe alternatives with similar pregnancy outcomes to those of women treated with insulin in those women averse to subcutaneous insulin injections (for a systematic review of the subject, see Nicholson et al\(^\text{157}\)). However, metformin does cross the placenta and it is not known yet whether it causes long-term metabolic programming effects in the offspring.

Conclusions and future prospects

Due to potential fetal programming and the ensuing transgenerational effects, the increases in the incidence of GDM may enhance the massive public health burden worldwide as ‘diabetes begets diabetes’\(^\text{22,156}\). There is an urgent need, therefore, to reduce the effects of GDM in pregnancy and to do it in light of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study finding that maternal glucose

### Table 3. Key remaining questions to optimise the treatment of gestational diabetes (GDM)

<table>
<thead>
<tr>
<th>Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do low-GI diets offer real benefits to women in the prevention or treatment of GDM, above and beyond benefits gained from the consumption of those diets that would limit excessive weight gain in pregnancy?</td>
</tr>
<tr>
<td>Are any benefits of the consumption of a low-GI diet to prevent or treat GDM equally applicable to non-Western and non-Caucasian populations?</td>
</tr>
<tr>
<td>Is exercise of direct benefit to the prevention or treatment of GDM? If exercise is of direct benefit, what level of exercise provides the most benefit to both the mother and her unborn baby, whilst remaining safe for them both?</td>
</tr>
<tr>
<td>Are there any long-term metabolic programming effects on the offspring of treating GDM with oral hypoglycaemic agents (particularly metformin)? If so, are they detrimental to health?</td>
</tr>
<tr>
<td>Are long-acting insulin analogues safe and efficacious for the treatment of GDM?</td>
</tr>
<tr>
<td>Are ‘closed-loop’ insulin delivery systems beneficial for the treatment of GDM?</td>
</tr>
</tbody>
</table>

GI, glycaemic index.
concentrations in the third trimester of pregnancy, even in the sub-diabetes range, are linearly related to risk of adverse pregnancy outcomes rather than there being a particular maternal glucose threshold below which it is 'safe' \(^9\). Clearly, only some of the risk factors for GDM can be modified: the easiest of which may be limiting pre-pregnancy weight which in theory can be achieved by dietary, exercise or even pharmacological means.

Even allowing for difficulties caused by differences in screening protocols and diagnostic thresholds, there are several key questions that still need answering to optimise the treatment of GDM (Table 3). First, for the dietary treatment and even prevention of GDM it is important to gain more convincing proof that low-GI diets and exercise offer real benefits to the pregnant woman. The treatment of GDM by oral hypoglycaemic agents appears to be safe in the short term, but potential long-term effects on the offspring are unknown and will require long-term follow-up. For treatment of GDM by insulin, the safety and efficacy of the use of long-acting insulin analogues need to be established as they may help improve maternal glycaemia more effectively than currently possible with conventional insulins. The efficacy and safety of the use of closed-loop technologies \(^1\) ('the artificial pancreas' consisting of a continuous glucose monitor, an insulin pump containing human insulin or a rapid-acting insulin analogue and a control algorithm linking the two) in pregnancy also needs to be ascertained. Whilst such systems have not been tested in pregnancy so far, early results from children and adolescents suggest that at present they appear to work well under basal conditions but they may be currently less able to adequately cope with high carbohydrate loads at meal times \(^1\). They may therefore be most effective in GDM when guidelines over the consumption of frequent small meals and snacks \(^9\), rather than large meals, are followed. In conclusion, there remain a number of key questions that need answering before regimens for treating GDM can be considered optimal. Recent efforts to clarify the diagnosis of GDM \(^4\) should help with the recruitment of more uniform populations to studies seeking to address such issues, which in turn should reduce the heterogeneity of the results they produce and aid the drawing of more definitive conclusions.

Acknowledgements

Funding for studies described in this paper that I have been involved in come from the Medical Research Council, The Wellcome Trust, The Evelyn Trust and National Institute for Health Research.

C. J. P. has no conflicts of interest to declare.

References

Recent advances in gestational diabetes


